It is not well-known yet how granulocyte colony-stimulating factor (G-CSF) affects nonischemic cardiomyopathy, though its beneficial effects on acute myocardial infarction are well-established. We hypothesize that G-CSF beneficially might affect nonischemic cardiomyopathy through the direct cardioprotective effects. Here, we show that a single injection of doxorubicin (DOX, 15 mg/kg) induced left ventricular dilatation and dysfunction in mice within 2 weeks, and that these effects were significantly attenuated by human recombinant G-CSF (100 mg/kg/day for 5 days). G-CSF also protected hearts against DOX-induced cardiomyocyte atrophy/degeneration, fibrosis, inflammatory cell infiltration and down regulation of GATA-4 and sarcomeric proteins, myosin heavy chain, troponin I and desmin, both in vivo and in vitro. Cardiac cyclooxygenase-2 was upregulated and G-CSF receptor was downregulated in DOX-induced cardiomyopathy, but both of those effects were largely reversed by G-CSF. No DOX-induced apoptotic effects were seen, nor were there any changes in tumor necrosis factor-a or transforming growth factor-b1 levels. Among downstream mediators of G-CSF receptor signaling, DOX-induced cardiomyopathy involved inactivation of extracellular signal-regulated protein kinase (ERK); the ERK inactivation was reversed by G-CSF. Inhibition of ERK activation, but not cyclooxygenase-2 inhibition, completely abolished beneficial effect of G-CSF on cardiac function. G-CSF did not promote differentiation of bone marrow cells into cardiomyocytes according to the experiment using green fluorescent protein-chimeric mice, and inhibition of CXCR4 þ cell homing using AMD3100 did not diminish the effect of G-CSF. Finally, G-CSF was also effective when administered after cardiomyopathy was established. In conclusion, these findings imply the therapeutic usefulness of G-CSF mainly through restoring ERK activation against DOX-induced nonischemic cardiomyopathy.
The antineoplastic drug doxorubicin (DOX) is effective in the treatment of a broad spectrum of hematogenous and solid human malignancies, but its clinical use is limited because of its adverse side effects: irreversible degenerative cardiomyopathy and congestive heart failure. 1, 2 The efficacy of DOX as a cytotoxic agent for the treatment of human tumors has prompted a search to find treatments that reduce or prevent the risk of cardiomyopathy and congestive heart failure. [3] [4] [5] So far, however, the ability of these treatments to protect the heart from DOX-induced damage has been limited.
Recent investigations revealed unexpected effects of hematopoietic cytokines on DOX-induced cardiotoxicity; we reported erythropoietin, 6 whereas another group reported thrombopoietin, 7 prevented cardiac dysfunction in DOXinduced cardiomyopathy in mice. More recently, Hou et al reported preventive effects of granulocyte colony-stimulating factor (G-CSF) on progressive worsening of cardiac function in DOX-induced cardiomyopathy in rats. 8 G-CSF has been applied to ischemic heart diseases, originally being expected to contribute to tissue regeneration because G-CSF can mobilize bone marrow-derived stem cells into peripheral blood. 9, 10 Recent studies have confirmed the effectiveness of G-CSF on ischemic heart diseases and revealed new mechanisms for the effect other than tissue regeneration, that is, acceleration of healing and direct tissue protection. [11] [12] [13] [14] [15] On the other hand, there has been only one study reporting benefits of G-CSF on nonischemic cardiomyopathy, 8 and thus little is known on the mechanisms for G-CSF to exert such effects. It would be much worthy to confirm the beneficial effects of G-CSF on DOX-induced cardiomyopathy in particular because of the clinical reason; G-CSF is already accepted for clinical use in combination with DOX to DOXinduced myelosuppression. Thus, if truly effective, G-CSF would be very easily translational to management of DOXinduced cardiomyopathy. In the present study, we examined the effects of G-CSF, both preventive and therapeutic, on DOX-induced cardiomyopathy and investigated the specific mechanisms underlying those effects.
MATERIALS AND METHODS Experimental Protocols
This study was approved by our Institutional Animal Research Committee and conformed to the animal care guidelines of the American Physiological Society. Cardiomyopathy was induced in male 10-week-old C57BL/6J mice (Chubu Kagaku) with a single intraperitoneal injection of doxorubicin hydrochloride (Kyowa Hakko) at the dose of 15 mg/kg in saline. In sham-treated mice, the same volume of saline was injected in a similar manner. Recombinant human G-CSF (Chugai Pharmaceutical Co) was administered subcutaneously at a dose of 100 mg/kg/day in saline, once a day from day 1 to day 5. We determined the dose of G-CSF (100 mg/kg) based on previous studies reporting cardioprotective effects of G-CSF. 13, 14 Although this dosage is extremely higher than the clinical dosage to humans (lower than 10 mg/day), it is generally believed that mice have a low sensitivity to human G-CSF as presumed by the unexpectedly poor increase in granulocytes. Untreated control groups were given the same volume of saline. G-CSF was administered either prophylactically or after establishment of DOX-induced cardiomyopathy (Figure 1 ).
Protocol 1
In this protocol, treatment with G-CSF was started just after administration of DOX to mice. Mice were randomly assigned to receive: (1) DOX alone (n ¼ 11), (2) DOX þ G-CSF (n ¼ 10), (3) saline alone (n ¼ 10) or (4) saline þ G-CSF (n ¼ 7) (Figure 1, Protocol 1a) . Two weeks later, all mice were killed with the overdose of pentobarbital following physiological examination. Cardiac specimens were then subjected to histological, immunohistochemical and molecular biological analyses.
In a second set of experiments (Protocol 1b), we evaluated the role played by the extracellular signal-regulated protein kinase (ERK) signaling pathway in mediating the effects of G-CSF. PD98059 (Cell Signaling), a MEK1-p42/p44 mitogenactivated protein kinase (MAPK)-specific inhibitor, 15 was administered intraperitoneally at a dose of 0.5 mg/kg/day for 5 days to mice given saline (n ¼ 6) or treated with DOX þ G-CSF (n ¼ 6). Two weeks later, mice were examined.
In a third set of experiments (Protocol 1c), the role for cyclooxygenase-2 activation was evaluated in mediating the effects of DOX. NS398, a specific cyclooxygenase-2 inhibitor (Cayman Chemical), 16 was dissolved in water and given at a dose of 3 mg/kg/day for 2 weeks to mice given saline (n ¼ 6) or those treated with DOX (n ¼ 6) (Figure 1 ). Mice were examined 2 weeks later.
In a fourth set of experiments (Protocol 1e), we tested the possibility that G-CSF induces bone marrow cell-derived myocardial regeneration. Bone marrow cells were harvested from the femurs and tibias of donor green fluorescent protein (GFP)-transgenic mice with a C57BL/6J background (a gift from Professor Susumu Ikehara, Kansai Medical School, Moriguchi, Japan). 17 The harvested cells were then transplanted directly into the tibial bone marrow of 8-week-old male C57BL/6J mice (n ¼ 15) that had received whole body irradiation as described previously. 18 Four weeks later, the 12 surviving chimeric mice were randomly assigned to receive:
; the dosages and methods were the same as described in Protocol 1a. On average, 8770.88% of the peripheral blood nucleated cells were positive for GFP in the recipients. Two weeks after DOX injection, all mice were killed and cardiac specimens were subjected to immunohistochemical analyses.
We also used another approach to further clarify the role for bone marrow cell homing in the effect of G-CSF on DOXinduced cardiomyopathy (Protocol 1f). In this fourth set of experiments, AMD3100 (octahydrochloride, Sigma), a specific CXCR4 antagonist, 19 was administered for 5 days at the dose of 200 mg/kg/day to mice given saline (n ¼ 6) or treated with DOX þ G-CSF (n ¼ 6). Two weeks later, all mice were given a physiological examination.
Protocol 2 (late treatment)
In this protocol, G-CSF treatment was started 2 weeks after DOX injection. At that time, mice were assigned to a G-CSFtreated group (n ¼ 8) or an untreated group (n ¼ 9). Before this assignment, echocardiography was carried out to reduce the bias between the groups. Four weeks after DOX injection, mice were examined as described for Protocol 1a (Figure 1) .
In a second set of experiments (Protocol 2b), we evaluated animals after a longer follow-up interval (10 weeks): mice received DOX alone or DOX þ G-CSF (n ¼ 13 each).
Protocol 3 ( in vitro experiments)
Cardiomyocytes were isolated from 1-day-old neonatal C57BL/6J mice as described previously, 20 and then plated on laminin-coated dishes or in slide glass chambers and incubated in DMEM (Sigma) supplemented with 10% FBS (Sigma) for 48 h at 371C. The cells were then treated with DOX at a concentration of 0.1 mmol/l in saline or with the same volume of saline alone. Simultaneously, G-CSF was added to the medium to a final concentration of 0, 1, 10, 50, 100, 1000 or 10 000 ng/ml. Survival rate of the in vitro cardiomyocytes was monitored by Trypan blue dye-exclusion at 0, 6, 12 and 24 h. Twenty-four hours later, the cells were subjected to morphometric and biochemical analyses. To examine effect of prophylactic use of G-CSF on DOX-induced cardiomyopathy, G-CSF administration was started immediately after DOX injection. Protocol 2: To examine the therapeutic effect of G-CSF on established DOX-induced cardiomyopathy, G-CSF was started at 2 weeks after DOX injection, when LV dysfunction is already apparent. Mice were examined at 4 or 10 weeks after DOX injection; the latter was to check whether the effect of G-CSF persists for a long interval. Protocol 3: In vitro experiments (see text for details).
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Proteins extracted from cardiomyocytes on dishes were used for Western blotting. The cells on slide glass chambers were fixed in 4% paraformaldehyde, permeabilized with 0.05% Triton-X and stained with rhodamine-phalloidin and Hoechst 33342 (both from Molecular Probes). Digital images captured using a confocal laser scanning microscope system (LSM510, Zeiss) were used for morphometric analysis using Adobe Photoshop 7.0 (Adobe Systems Inc.).
Physiological Studies
Echocardiograms were recorded using an echocardiographic system (Aloka) equipped with a 7.5-MHz imaging transducer as described previously. 21 After cardiac echocardiography, the right carotid artery was cannulated with a micromanometertipped catheter (SPR 671; Millar Instruments) and advanced into the aorta and then into the left ventricle (LV) for recording pressure and 7dP/dt.
Histological Analysis
After echocardiography, each heart was removed and cut into three transverse slices. Of those, the middle slice was fixed with 10% buffered formalin and embedded in paraffin, after which 4-mm-thick sections were stained with H&E or Sirius red F3BA (0.1% solution in saturated aqueous picric acid) (Aldrich). Quantitative assessments, including cell size and fibrotic area, were carried out using a multipurpose color image processor (LUZEX F; Nireco, Kyoto, Japan) with 20 randomly chosen high-power fields (HPFs) in each heart.
Immunohistochemical Analysis
Tissue sections (4-mm-thick deparaffinized sections from the middle third of the ventricle or 8-mm-thick cryosections from the apical third of the ventricle) were incubated with a primary antibody against G-CSF receptor (G-CSFR), Flk-1, myosin heavy chain (MHC) (all from Santa Cruz), GFP (Molecular Probes), a-smooth muscle actin (a-SMA) (Sigma) or CD45 (Pharmingen). An ABC kit (DAKO) was then used for immunostaining with diaminobenzidine serving as the chromogen. For immunofluorescence, Alexa Fluor 568 and 488 (Molecular Probes) were the secondary antibodies. Nuclei were counterstained with hematoxylin or Hoechst 33342. The primary antibodies were substituted with the respective control IgG for the control sections. Sections were observed under a light or confocal microscope. For morphometrical analysis of specimens with immunofluorescence, digital images captured using a laser-confocal microscope system (LSM510, Zeiss) were employed for morphometric and quantitative analyses using Adobe Photoshop 7.0 software (Adobe Systems Inc); the number of immunopositive cells (GFP-or CD45-positive cells) was counted using randomly chosen 10 images per tissue section (4 mm).
Cell Death Assays
Previous studies have demonstrated that DOX increases the number of apoptotic cardiomyocytes and induces heart failure. 22, 23 To detect apoptosis, the in situ nick end-labeling (TUNEL) assay was carried out in sections using an ApopTag kit (Intergene) principally according to the supplier's instructions. Mouse mammary tissue served as a positive control. Also, sarcolemmal integrity was assessed by living stain with Evans blue dye. The dye is excluded by cells with normal sarcolemmal permeability but taken up by those with leakier cell membranes including dead cells. 24 In the animals injected with Evans blue dye 1 day before examination, the hearts were excised and cryosections were examined under a fluorescent microscope. The number of TUNEL-and Evans blue-positive cells was counted in each whole ventricular section. Both TUNEL assay and Evans blue staining were performed in the mice at 1, 3, 7 and 14 days (n ¼ 3 each) after treatment with saline or DOX.
Electron Microscopy
Cardiac specimens were immersion-fixed overnight in phosphate-buffered 2.5% glutaraldehyde (pH 7.4), postfixed for 1 h with 1% osmium tetroxide, dehydrated through a graded ethanol series, and embedded in Epon medium. Ultrathin sections were stained with uranyl acetate and lead citrate and observed in an electron microscope (H700, Hitachi, Tokyo, Japan).
Western Analysis
Heart tissue lysates were used for Western analysis. Proteins were separated and transferred to membranes using standard protocols, after which they were probed using antibodies against G-CSFR, GATA-4, MHC, troponin I (all from Santa Cruz), desmin (Sigma), COX-2 (Santa Cruz) or transforming growth factor-b1 (TGF-b1, Promega). Activation of Akt, signal transducer and activator of transcription-3 (STAT3) and ERK, downstream mediators of G-CSFR signaling, was assessed using antibodies against the phosphorylated forms of Akt (p-Akt), p-STAT3 and p-ERK (all from Cell Signaling). Procaspase-3 and the activated form of caspase-3 were evaluated using anti-caspase-3 antibody (Santa Cruz). Three to five hearts from each group were subjected to the blotting. The blots were visualized by means of chemiluminescence (ECL, Amersham), and the signals were quantified by densitometry. a-tubulin (analyzed by antibody from Santa Cruz) served as the loading control.
ELISA
Levels of tumor necrosis factor-a (TNF-a) in the myocardium were assayed using an ELISA (R&D Systems). Three hearts from each group were used for this assay.
Statistical Analysis
Value are shown as means7s.e.m. The significance of differences between groups was evaluated using t-tests or oneway ANOVA followed by Newman-Keul's multiple comparison test. Values of Po0.05 were considered significant.
RESULTS

Effects of Prophylactic Use of G-CSF on DOX-Induced Cardiomyopathy
In Protocol 1a (Figure 1 ), G-CSF was administered at the dose of 100 mg/kg/day for 5 days, beginning immediately after a single injection of DOX (15 mg/kg) to mice. Two weeks after DOX administration, all of the mice in the untreated (n ¼ 11) and G-CSF-treated (n ¼ 10) groups and in the sham groups (untreated, n ¼ 10 and G-CSF-treated, n ¼ 7) were alive. Granulocyte count on the day after the last treatment were significantly greater in the G-CSF-treated groups (sham, 37137511/ml; DOX, 32187644/ml) than the salinetreated (sham, 13227205/ml (Po0.05); DOX, 471789/ml (Po0.05)) groups, but had returned to control levels by the time of sacrifice (2 weeks later).
Echocardiography and cardiac catheterization showed that, as compared with sham animals, mice receiving DOX alone had significant deterioration of LV functionality characterized by enlargement of the LV cavity and increased LV diameters (LVDd, 3 (Figure 2 ). Treatment with G-CSF significantly mitigated the DOXinduced impairment of cardiac function (LVDd, 3.17 0.042 mm; LVEDP, 2.470.38 mm Hg; LVFS, 2770.79%; þ dP/dt, 78527390 mm Hg/sec; ÀdP/dt, À71087419 mm Hg/s (all Po0.05 compared with the saline-treated group)). Administration of G-CSF had no effect on cardiac function of the sham mice.
We observed no significant difference in the heart-to-body weight ratios among the groups in Protocol 1a (sham, 3.7170.05 mg/g; G-CSF alone, 3.7970.15 mg/g; DOX alone, 3.8670.10 mg/g; DOX plus G-CSF, 3.8370.12 mg/g (P ¼ NS)). On the other hand, examination of transverse sections of hearts stained with H&E (Figure 3a) revealed that the transverse diameters of cardiomyocytes from the group receiving DOX alone were significantly smaller than in the sham group (13.770.1 vs 14.670.1 mm (Po0.05)), and that G-CSF exerted a significant protective effect against such DOX-induced cardiomyocyte atrophy (transverse diameter, 14.570.3 mm (Po0.05)) (Figure 3b) . Similarly, when we assessed myocardial fibrosis using Sirius red-stained sections, we found significantly more fibrosis in the group receiving DOX alone than in the sham group (1.0170.10 vs 0.427 0.05% (Po0.05)) or the group receiving DOX þ G-CSF (0.6870.04% (Po0.05)) (Figure 3 ). In addition, immunohistochemical analysis revealed that DOX initiated significant infiltration of the myocardium by CD45-positive leukocytes (9.871.1 vs 5.270.6 cells/HPF in the sham group (Po0.05)), and again G-CSF attenuated DOX's effect, reducing the leukocyte infiltration to 4.670.2 cells/HPF (Po0.05). There was no significant difference in the number of Flk-1-positive endothelial cells among the groups (Figure 3) .
Degenerative changes within cardiomyocytes caused by DOX were clearly evident on electron micrographs, which confirmed previously described findings in DOX cardiomyopathy. 6, 25 These changes were characterized by myofibrilar derangement and disruption and by increases in the volumes of subcellular organelles (Figure 4 ). These degenerative changes were significantly attenuated by treatment with G-CSF.
TUNEL-positive cells were observed among both cardiomyocytes and noncardiomyocytes from all groups, and we found no significant difference in the incidence of TUNEL positivity between mice that received DOX (0.1370.048% in myocytes; 0.02170.011% in nonmyocytes) and those that did not (0.08470.056% in myocytes; 0.03570.021% in nonmyocytes (both P ¼ NS)); G-CSF had no significant effect on the incidence of TUNEL positivity (0.09370.064% in myocytes; 0.03670.017% in nonmyocytes (both P ¼ NS)) ( Figure 4 ). Consistent with those findings, we detected no activated caspase-3 in any of the groups. And although as mentioned above electron microscopy revealed degenerative changes within cardiomyocytes from DOX-treated mice (Figure 4 ), typical apoptotic ultrastructure was never seen. We also found no Evans blue-positive cardiomyocytes in any mice that received DOX or not at any time points examined (Figure 4) . Collectively, neither apoptosis nor death of cardiac cells seems to be critically involved in the present model of DOX-induced cardiomyopathy whereas DOX-induced degenerative changes were apparent in the cardiomyocytes.
No adverse reactions to G-CSF, including splenic rupture, thromboembolism, interstitial pneumonia and atherosclerosis, were detected.
Mechanisms for Beneficial Effect of G-CSF on DOX-Induced Cardiomyopathy GATA-4 is a key transcriptional factor regulating expression of sarcomeric proteins in the heart. 26, 27 We found myocardial levels of GATA-4 to be significantly reduced by DOX ( Figure  3) , confirming earlier reports. 22, 23 We also found that this reduction was partially but significantly restored by G-CSF treatment ( Figure 5 ). Likewise, levels of three sarcomeric proteins, MHC, troponin I and desmin, were significantly reduced by DOX, and this inhibitory effect was also significantly reversed by G-CSF. DOX had no significant effect on myocardial expression of TNF-a or TGF-b1; however, cyclooxygenase-2 expression was markedly upregulated by DOX, and that effect was largely reversed by G-CSF ( Figure  6 ). Western analysis revealed that expression of G-CSF receptor (G-CSFR) was significantly diminished in DOXtreated hearts, but was greatly enhanced by G-CSF treatment (Figure 7a ). Consistent with this finding, immunohistochemical analysis showed G-CSFR to be expressed on cardiomyocytes and to be more strongly expressed in G-CSFtreated hearts (Figure 7a) . ERK/MAPK, receptor-associated Janus family tyrosine kinase (Jak)/STAT and/or phosphatidylinositol 3-kinase (PI3K)/Akt are known to serve as downstream mediators of G-CSFR signaling in hematopoietic cell lines 28, 29 and myocardium. 14 We found that neither DOX-induced cardiomyopathy nor the effects of G-CSF were related to activation (phosphorylation) of Akt or STAT3 (Figure 7b ). On the other hand, ERK phosphorylation, and thus its activation, was markedly inhibited by DOX, and that effect was significantly attenuated by G-CSF (Figure 7b ). To further confirm the critical role played by ERK in mediating the cardioprotective effects of G-CSF, we next tested the effect of inhibiting ERK activation using the MEK1-p42/p44 MAPK-specific inhibitor PD98059 (Protocol 1b). When administered to mice along with DOX þ G-CSF, PD98059 suppressed ERK activation and GATA-4 expression to the same level seen in untreated DOXinduced cardiomyopathy (Figure 8a) . Moreover, PD98059 completely eliminated the G-CSF-mediated improvement in cardiac function and histology (Figure 8b and c) , suggesting that the ERK pathway is critically involved in the protective To evaluate the role for COX-2 activation in mediating the effect of DOX on the heart of the present model, we checked the effect of inhibiting cyclooxygenase-2 activation using the specific cyclooxygenase-2 inhibitor NS398 (Protocol 1c). This experiment revealed that NS398 could not beneficially affect cardiac function in DOX-induced cardiomyopathy although it partially suppressed myocardial inflammation and fibrosis (Figure 8b and c) . In addition, NS398 was confirmed not to reverse DOX-induced ERK inactivation and GATA-4 reduction (Figure 6d ). On the other hand, ERK inhibition by PD98059 did not restore the downregulated COX-2 by G-CSF (Figure 8e) .
In an experiment using chimeric mice transplanted with GFP transgenic mouse-derived bone marrow cells (Protocol 1e), we observed no significant effect of G-CSF on mobilization and cardiac homing of bone marrow cells (Figure 9 ). That is, our examination of cellular immunofluorescence revealed no cardiomyocytes, endothelial cells or a-SMApositive vascular smooth muscle cells originating from GFPpositive cells; some CD45-positive cells expressing GFP were detected in the myocardium, however (Figure 9 ). AMD3100 is a specific CXCR4 antagonist that prevents homing of CXCR4 þ cells. When administered to mice receiving DOX þ G-CSF (Protocol 1f), AMD3100 had no effect on the G-CSFmediated improvement in cardiac function (Figure 8b ).
Effects of G-CSF on Established DOX-Induced Cardiomyopathy
Using Protocol 2 (Figure 1) , we next examined the therapeutic efficacy of G-CSF on established LV dysfunction resulting from DOX-induced cardiomyopathy (late treatment). In this experiment, G-CSF treatment was started 2 weeks after DOX injection, at which time LV dysfunction was readily apparent; animals were then examined 2 weeks later. Under these conditions, we found that G-CSF still had significant beneficial, and thus therapeutic, effects on DOXinduced cardiomyopathy (Table 1) .
We next evaluated longer effect of G-CSF on DOX-induced cardiomyopathy (Figure 1, Protocol 2b) . The survival rate of mice in Protocol 2b was similar between the salineand G-CSF-treated groups (77 vs 77%). However, as shown in Table 2 , we noted that a significant cardiac protection by G-CSF persisted for a long interval because the cardiac function was significantly better even after the follow-up for 10 weeks.
In Vitro Effects of G-CSF on Cardiac Cells (Protocol 3)
Cultured cardiomyocytes incubated in the presence of DOX (0.1 mmol/l) showed significant atrophy/degeneration. G-CSF treatment significantly diminished the DOX-induced cardiomyocyte atrophy (Figure 10a) . The effect of G-CSF on cardiomyocytes was dose-dependent and reached a maximum at a concentration of 100 ng/ml. Western analysis revealed that DOX significantly reduced expression of GATA-4 and MHC in cultured cardiomyocytes, both of which were restored by G-CSF treatment (Figure 10b ). In addition, DOX significantly increased expression of cyclooxygenase-2, and that effect, too, was significantly reversed by G-CSF (Figure 10c) . Thus, G-CSF appears to act directly on cardiomyocytes to exert its anti-atrophic and anti-inflammatory effects. DOX at the present concentration did not affect the time course of the survival rate of cardiomyocytes (Figure 4) . 
G-CSF effect on cardiomyopathy L Li et al
DISCUSSION G-CSF Exerts a Protective Effect Against DOX-Induced Cardiomyopathy
The present study provides the evidence of the beneficial effects of G-CSF on LV dysfunction caused by DOX-induced cardiomyopathy, a nonischemic cardiomyopathy. The principle pathologic findings were that G-CSF prevented DOXinduced atrophic degeneration of cardiomyocytes and cardiac fibrosis. The mechanism of action of G-CSF in this model differs from that seen in cases of myocardial infarction, where G-CSF reportedly enhances the survival of ischemic cardiomyocytes. 13, 14 What's more, G-CSF also exerted a therapeutic effect on DOX-induced cardiac dysfunction and histopathologic changes after the cardiomyopathy had become established.
Mechanisms Underlying the Cardioprotective Effects of G-CSF Our findings suggest that several factors contribute to the cardioprotective effects of G-CSF on DOX-induced cardiomyopathy. The first is that G-CSF mitigates the evoked atrophic degeneration of cardiomyocytes. Sarcomeric proteins, including MHC, troponin I and desmin, are important for the structural integrity and function of cardiomyocytes, and their myocardial expression is reportedly downregulated by DOX, 5 an effect we confirmed in the present study. Our new finding is that G-CSF significantly restores the expression of sarcomeric proteins in the presence of DOX. We suggest that GATA-4 is involved in this anti-atrophic effect, as GATA-4 is a key regulator of heart development that also is known to regulate myocardial expression of MHC and troponin I 26, 27 and was recently shown to be depleted in DOXinduced cardiotoxicity. 22, 23 Our results not only confirmed that earlier finding, but also demonstrated that G-CSF restores GATA-4 expression in the presence of DOX.
In hematopoietic and cardiac cells, G-CSFR signaling can activate ERK/MAPK, PI3K/Akt and Jak/STAT3 signaling pathways. 14, 28, 29 Our findings suggest that altered signaling via ERK, but not Akt or STAT3, is involved in DOX-induced cardiomyopathy, which is consistent with a very recent study showing that ERK activation is significantly diminished during the chronic stage of DOX-induced cardiomyopathy (3 weeks after DOX injection). 30 Given that another study using isolated rat heart subjected to excessive LV wall stress (induced by balloon inflation) showed an involvement of MAPK (p38 and ERKs) in the activation of GATA-4 binding to DNA, 31 we suggest that G-CSF exerts its cardioprotective effects via the ERK/MAPK signaling pathway, which was otherwise inhibited by DOX. We recently showed that G-CSF improved cardiac function of the mouse heart with a large old MI. 21 In that model, G-CSF-induced molecular signaling downstream of G-CSFR differed substantially from that seen in the present model despite the animal species used was same. Stat and Akt activation was augmented in the mouse heart with old MI, which was furthermore strengthened by G-CSF, whereas ERK activation was not influenced by G-CSF. Thus, G-CSF's downstream signal via G-CSFR apparently varies in different models of heart failure.
We observed that DOX stimulates both myocardial infiltration by inflammatory cells and the development myocardial fibrosis, and that G-CSF prevents these pathological processes. Similar anti-inflammatory properties of G-CSF were observed previously in the central nervous system and in monocytes. 32, 33 In the heart, induction of a powerful inflammatory mediator is reportedly associated with heart failure. 34 Although earlier studies reported TNF-a and TGFb1 to be potent stimulators of inflammation and fibrosis in the failing heart, 35, 36 their involvement in DOX-induced cardiomyopathy was challenged in a recent report. 37 Consistent with the latter, we found no significant DOX-or G-CSF-induced changes in the expression of TNF-a and TGFb1. On the other hand, it is known that DOX induces myocardial expression cyclooxygenase-2, 38 which occupies a central position in the biosynthesis of proinflammatory prostaglandin E2, prostacyclin and thromboxane A 2 , and that inhibition of cyclooxygenase-2 improves cardiac function in DOX-induced cardiomyopathy. 39 Actually, we noted that DOX strongly induced myocardial cyclooxygenase-2 expression in the present study and that this effect was largely inhibited by G-CSF. However, we also found that inhibition of cyclooxygenase-2 by a specific cyclooxygenase-2 inhibitor could not mimic the effect of G-CSF on DOX-induced cardiomyopathy: no improvement in cardiac function or no restoration of cardiomyocyte size, though with partial reduction in myocardial inflammation and fibrosis. PD98059 and NS398 did not affect, respectively, cyclooxygenase-2 expression and ERK activation. Collectively, these findings indicate that myocardial fibrosis and inflammation induced by DOX may be regulated by cyclooxygenase-2 upregulation although these phenotypes are unlikely to profoundly affect the cardiac function and that anti-atrophic/degenerative action of G-CSF on cardiomyocytes that is accompanied by ERK-mediated GATA-4 expression is the most important mechanism of the beneficial effects of G-CSF against cardiac dysfunction in DOX-induced cardiomyopathy.
Our immunohistochemical and Western blot analyses showed strong myocardial expression of G-CSFR, which confirms earlier reports.
14, 21 We also found that DOX significantly downregulated myocardial G-CSFR expression and that this inhibitory effect was completely blocked by G-CSF. The mechanism by which DOX downregulates G-CSFR expression is entirely unknown, though DOX reportedly inhibits calcium-independent phospholipase A 2 . 40 It is thus tempting to speculate that inhibition of phospholipase A 2 by DOX critically impairs plasma membrane function, which in turn inhibits insertion of G-CSFR into the cardiomyocyte plasma membrane. Recent findings suggest that apoptosis among cardiomyocytes is a leading cause of cardiac dysfunction in DOXinduced cardiomyopathy, 41 although this hypothesis is still controversial, because of the lack of evidence of apoptotic morphology in those cardiomyocytes. 25, 42 Hou et al attributed anti-apoptotic effect of G-CSF in DOX-induced cardiomyopathy to the beneficial mechanism. 8 However, they depended on the TUNEL assay to detect apoptosis of which incidence was too high (more than 13% of the cardiomyocytes) to approve and they failed in demonstrating apoptotic morphology in their electron microscopic analysis. 8 Seeking evidence of DOX-induced apoptosis/cell death, we conducted a series of Evans blue living stains, TUNEL assays, electron microscopic examinations, analyses of myocardial caspase-3 activation, but we detected no effect of DOX or G-CSF on the incidence of apoptosis/cell death. Our findings thus suggest that cardiomyocyte apoptosis is not important for disease progression in the present model. The present model was given DOX in a single time and the survival rate was 100% in each group. These suggest that DOX insult in our model may be too weak to induce death in cardiac cells, compared with the previous ones. This may hold true also in our in vitro model.
Study Limitations
Generated reactive oxygen species (ROS) and calcium overload are believed to be most important mediators of DOX toxicity to the heart, [1] [2] [3] 41 although many other mechanisms are also proposed. These mediators are presumed to be positioning most upstream among signals evoked by DOX. The present study, however, did not address the possible influence of G-CSF on them. Investigations of this interesting topic are warranted.
Phenotypes and molecular signals evoked by G-CSF here were strikingly similar to those by erythropoietin in our previous study using the same animal model of DOX-induced cardiomyopathy that is, anti-atrophic degeneration of cardiomyocytes, anti-fibrosis, restoration of ERK, GATA-4, and sarcomeric proteins, and inhibition of cyclooxygenase-2, although we did not note a therapeutic effect in case of erythropoietin. 6 Although the intervention is different, many of the findings are quite similar. Thus, some comparative analysis between them is needed in future.
G-CSF has been reported to be angiogenic, 12-14 but we detected no DOX-induced reduction in capillary density, nor did G-CSF promote capillary outgrowth, indicating no mechanistic role for angiogenesis in DOX-induced cardiomyopathy or the cardioprotective effects of G-CSF. G-CSF also reportedly enhances postinfarct myocardial regeneration by mobilizing bone marrow-derived cells to the myocardium. 11, 12 In the present model, however, we did not find that G-CSF promoted differentiation of bone marrow-derived cells into cardiomyocytes, endothelial cells or vascular smooth muscle cells. Moreover, inhibition of CXCR4 þ cell homing by AMD3100 did not diminish the beneficial effect of G-CSF on cardiac function. Apparently, myocardial regeneration contributes little, if anything, to the effect of G-CSF on DOX-induced cardiomyopathy. However, the present study did not address myocardial regeneration by resident cardiac stem cells 43 and a possible effect of G-CSF on it remains unresolved. 
Conclusions
The present study not only confirms preventive effects, but also provides the first evidence of therapeutic effects of G-CSF against DOX-induced cardiomyopathy. These effects include attenuation of atrophic degeneration of cardiomyocytes and reduction of myocardial fibrosis, accompanied by restoration of myocardial expression of GATA-4 and sarcomeric proteins and suppression of COX-2 expression. Inhibition studies suggested that activated ERK-mediated antiatrophic degeneration effect might be the most important mechanism for the cardioprotection by G-CSF.
